Trial Profile

DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Aspirin
Indications Cardiovascular disorders; Chronic limb-threatening ischemia; Peripheral arterial disorders
Focus Therapeutic Use
Acronyms DUAL-PAD

Most Recent Events

13 Jan 2022 Status changed from recruiting to completed.
27 Jun 2021 Planned number of patients changed from 330 to 159.
02 Nov 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com